405 related articles for article (PubMed ID: 12621012)
1. Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts.
Subbiah K; Hamlin DK; Pagel JM; Wilbur DS; Meyer DL; Axworthy DB; Mallett RW; Theodore LJ; Stayton PS; Press OW
J Nucl Med; 2003 Mar; 44(3):437-45. PubMed ID: 12621012
[TBL] [Abstract][Full Text] [Related]
2. Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas.
Pagel JM; Hedin N; Subbiah K; Meyer D; Mallet R; Axworthy D; Theodore LJ; Wilbur DS; Matthews DC; Press OW
Blood; 2003 Mar; 101(6):2340-8. PubMed ID: 12446461
[TBL] [Abstract][Full Text] [Related]
3. A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts.
Press OW; Corcoran M; Subbiah K; Hamlin DK; Wilbur DS; Johnson T; Theodore L; Yau E; Mallett R; Meyer DL; Axworthy D
Blood; 2001 Oct; 98(8):2535-43. PubMed ID: 11588052
[TBL] [Abstract][Full Text] [Related]
4. Comparison of a tetravalent single-chain antibody-streptavidin fusion protein and an antibody-streptavidin chemical conjugate for pretargeted anti-CD20 radioimmunotherapy of B-cell lymphomas.
Pagel JM; Lin Y; Hedin N; Pantelias A; Axworthy D; Stone D; Hamlin DK; Wilbur DS; Press OW
Blood; 2006 Jul; 108(1):328-36. PubMed ID: 16556891
[TBL] [Abstract][Full Text] [Related]
5. A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations.
Pagel JM; Orgun N; Hamlin DK; Wilbur DS; Gooley TA; Gopal AK; Park SI; Green DJ; Lin Y; Press OW
Blood; 2009 May; 113(20):4903-13. PubMed ID: 19124831
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy of 177Lu and 90Y for anti-CD20 pretargeted radioimmunotherapy in murine lymphoma xenograft models.
Frost SH; Frayo SL; Miller BW; Orozco JJ; Booth GC; Hylarides MD; Lin Y; Green DJ; Gopal AK; Pagel JM; Bäck TA; Fisher DR; Press OW
PLoS One; 2015; 10(3):e0120561. PubMed ID: 25785845
[TBL] [Abstract][Full Text] [Related]
7. Radioimmunotherapy of A431 xenografted mice with pretargeted B3 antibody-streptavidin and (90)Y-labeled 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-biotin.
Yao Z; Zhang M; Axworthy DB; Wong KJ; Garmestani K; Park L; Park CW; Mallett RW; Theodore LJ; Yau EK; Waldmann TA; Brechbiel MW; Paik CH; Pastan I; Carrasquillo JA
Cancer Res; 2002 Oct; 62(20):5755-60. PubMed ID: 12384535
[TBL] [Abstract][Full Text] [Related]
8. Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody.
Sharkey RM; Karacay H; Litwin S; Rossi EA; McBride WJ; Chang CH; Goldenberg DM
Cancer Res; 2008 Jul; 68(13):5282-90. PubMed ID: 18593929
[TBL] [Abstract][Full Text] [Related]
9. Pretargeted radioimmunotherapy using genetically engineered antibody-streptavidin fusion proteins for treatment of non-hodgkin lymphoma.
Park SI; Shenoi J; Frayo SM; Hamlin DK; Lin Y; Wilbur DS; Stayton PS; Orgun N; Hylarides M; Buchegger F; Kenoyer AL; Axtman A; Gopal AK; Green DJ; Pagel JM; Press OW
Clin Cancer Res; 2011 Dec; 17(23):7373-82. PubMed ID: 21976541
[TBL] [Abstract][Full Text] [Related]
10. In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy.
Lewis MR; Wang M; Axworthy DB; Theodore LJ; Mallet RW; Fritzberg AR; Welch MJ; Anderson CJ
J Nucl Med; 2003 Aug; 44(8):1284-92. PubMed ID: 12902420
[TBL] [Abstract][Full Text] [Related]
11. Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemia.
Pagel JM; Matthews DC; Kenoyer A; Hamlin DK; Wilbur DS; Fisher DR; Gopal AK; Lin Y; Saganic L; Appelbaum FR; Press OW
Cancer Res; 2009 Jan; 69(1):185-92. PubMed ID: 19118002
[TBL] [Abstract][Full Text] [Related]
12. Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma.
Sharkey RM; Karacay H; Johnson CR; Litwin S; Rossi EA; McBride WJ; Chang CH; Goldenberg DM
J Nucl Med; 2009 Mar; 50(3):444-53. PubMed ID: 19223402
[TBL] [Abstract][Full Text] [Related]
13. Comparative biodistributions of pretargeted radioimmunoconjugates targeting CD20, CD22, and DR molecules on human B-cell lymphomas.
Pantelias A; Pagel JM; Hedin N; Saganic L; Wilbur S; Hamlin DK; Wilbur DS; Lin Y; Stone D; Axworthy D; Gopal AK; Press OW
Blood; 2007 Jun; 109(11):4980-7. PubMed ID: 17303693
[TBL] [Abstract][Full Text] [Related]
14. Improved therapy of non-Hodgkin's lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibody.
Sharkey RM; Karacay H; Chang CH; McBride WJ; Horak ID; Goldenberg DM
Leukemia; 2005 Jun; 19(6):1064-9. PubMed ID: 15815716
[TBL] [Abstract][Full Text] [Related]
15. Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease.
Park SI; Shenoi J; Pagel JM; Hamlin DK; Wilbur DS; Orgun N; Kenoyer AL; Frayo S; Axtman A; Bäck T; Lin Y; Fisher DR; Gopal AK; Green DJ; Press OW
Blood; 2010 Nov; 116(20):4231-9. PubMed ID: 20702781
[TBL] [Abstract][Full Text] [Related]
16. Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Studies in a human colon cancer xenograft model.
Sharkey RM; Karacay H; Griffiths GL; Behr TM; Blumenthal RD; Mattes MJ; Hansen HJ; Goldenberg DM
Bioconjug Chem; 1997; 8(4):595-604. PubMed ID: 9258460
[TBL] [Abstract][Full Text] [Related]
17. Applying near-infrared photoimmunotherapy to B-cell lymphoma: comparative evaluation with radioimmunotherapy in tumor xenografts.
Heryanto YD; Hanaoka H; Nakajima T; Yamaguchi A; Tsushima Y
Ann Nucl Med; 2017 Nov; 31(9):669-677. PubMed ID: 28741052
[TBL] [Abstract][Full Text] [Related]
18. Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model.
Green DJ; Shadman M; Jones JC; Frayo SL; Kenoyer AL; Hylarides MD; Hamlin DK; Wilbur DS; Balkan ER; Lin Y; Miller BW; Frost SH; Gopal AK; Orozco JJ; Gooley TA; Laird KL; Till BG; Bäck T; Sandmaier BM; Pagel JM; Press OW
Blood; 2015 Mar; 125(13):2111-9. PubMed ID: 25628467
[TBL] [Abstract][Full Text] [Related]
19. Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies.
Ma D; McDevitt MR; Barendswaard E; Lai L; Curcio MJ; Pellegrini V; Brechbiel MW; Scheinberg DA
Leukemia; 2002 Jan; 16(1):60-6. PubMed ID: 11840264
[TBL] [Abstract][Full Text] [Related]
20. Pretargeted radioimmunotherapy with a single-chain antibody/streptavidin construct and radiolabeled DOTA-biotin: strategies for reduction of the renal dose.
Förster GJ; Santos EB; Smith-Jones PM; Zanzonico P; Larson SM
J Nucl Med; 2006 Jan; 47(1):140-9. PubMed ID: 16391198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]